Insights, Knowledge Gaps, and Priorities in Marginal Zone Lymphoma Research
Marginal Zone Lymphoma experts discussed recent advancements in all areas of MZL, while calling attention to gaps in knowledge in the 2024 MZL Scientific Workshop.
Navigating Management and Dosing Considerations for Amivantamab in NSCLC
Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.
Aggressive Thyroid Screening/Treatment Not Associated With Higher Survival
A population-based study led by Cedars-Sinai investigators found that thyroid cancer continues to be overdiagnosed, while the risk of dying from the disease has remained the same.
Clinical Trials Underestimate HRQOL Burden on R/R Myeloma Population
A retrospective systemic literature review showed that increased lines of therapy led to decreased HRQOL in patients with relapsed/refractory myeloma.
Managing Brain Metastases in Patients with HER2+ Metastatic Breast Cancer
The panel discussed the different ways to treat patients with HER2-positive metastatic breast cancer who also have brain metastases.
Orphan Drug Designation Granted to 225Ac-SSO110 for SCLC
Following promising results from a trial investigating the effects of 225Ac-SSO110 on Balb/c nude mice injected with the xenograft model of SCLC, IND clearance was granted by the FDA.
Hormone Therapy Confers Modest Breast Cancer Risk Even With Family History
Risk model data may provide reassurance for individuals undergoing hormone therapy with an already heightened breast cancer risk due to family history.
Intricacies of EGFR-Mutated NSCLC Care From the Patient Perspective
Alexander Spira, MD, and Julia Lazo, RN, spoke with Melinda Reubens, who was diagnosed with EGFR-mutant NSCLC, and her husband Justin.
FT596 Shows Favorable Tolerability, Response Rate in B-Cell Lymphoma
Completion of the phase 1 first-in-human trial revealed that iPSC-derived CAR natural killer cell therapy has potential for development across oncology.
Program Evaluating TIDAL-01 in Solid Tumors Has Been Discontinued
The decision impacts the phase 1 STARLING trial and additional phase 1 trials sponsored by the Moffitt Cancer Center evaluating TIDAL-01 in solid tumors.
Ziftomenib Monotherapy Shows Positive Topline Results in NPM1-Mutant AML
Ziftomenib elicited positive responses in patients with NPM1-mutant acute myeloid leukemia, meeting the primary end point of the phase 2 KOMET-001 trial.
MZL Workshop Paves the Way for Better Treatment Options
Thomas Habermann, MD, discusses the significance of the MZL Workshop and its contributions to advancing research and improving outcomes.
Evaluating Ways to Maximize Immunotherapy Use in NSCLC
“We have huge amounts of work to do to maximize the efficacy of immunotherapy,” Christine Bestvina, MD, said during an interview with CancerNetwork.
Personalized Vaccines Elicit Anti-Cancer Immune Responses in Kidney Cancer
All 9 patients in a phase 1 trial testing a neoantigen-targeting personalized cancer vaccine in renal cell carcinoma had no recurrence at data cutoff.
Talquetamab Combo Data Warrant Further Research in R/R Multiple Myeloma
Findings from RedirecTT-1 show responses across different dose levels of talquetamab/teclistamab among those with multiple myeloma.
MZL Expert Insights Summit Sponsored by the Lymphoma Research Foundation
Julie M. Vose, MD, MBA, discussed MZL research and future directions in the February Letter to Readers.
Personalized Immunotherapy Earns FDA RMAT Status in Advanced Ovarian Cancer
Phase 2b data support the Regenerative Medicine Advanced Therapy designation for gemogenovatucel-T in newly diagnosed advanced ovarian cancer.
Radiation Combo Elicits Efficacy in Advanced NSCLC With Brain Metastases
Radiotherapy plus camrelizumab and platinum-doublet chemotherapy showed manageable toxicity in untreated non–small cell lung cancer with brain metastases.
Targeted Therapies/Immunotherapy Have Made Promising Changes in NSCLC Treatment
Christine Bestvina, MD, stated that the presence of EGFR and ALK mutations can affect the way that a patient will react to treatment and should be factors that physicians consider.
Pembrolizumab Combo Enhances Response Rate in ER+/HER2– Breast Cancer
The safety profile of pembrolizumab plus neoadjuvant chemotherapy was consistent with the known profiles for each treatment.
AI/ML-Based Software Improves Diagnostic Accuracy in Lung Cancer
The diagnostic accuracy of radiologists aided by the eyonis LCS AI software was greatly improved compared with when radiologists were unaided.
Updated Results Show THIO/Cemiplimab Improves Median OS in Advanced NSCLC
6-thio-2’-deoxyguanosine sequenced plus cemiplimab elicited an OS of 16.9 months in the third-line setting for patients with advanced non–small cell lung cancer.
Frontline Treatment Options in EGFR-Mutated NSCLC Show Promise
“We need some longer-term overall survival data to help discuss with patients the best treatment of choice for them,” Christine Bestvina, MD, said.
Thyroidectomy Shows Noninferiority Without Radioiodine in Thyroid Cancer
A greater proportion of excellent responses were reported without radioiodine than with radioiodine when treating patients with low-risk thyroid cancer.
CHIP-Carrying Multiple Myeloma Correlates With More Aggressive Disease
Clonal hematopoiesis may be associated with the early development of toxic events in patients with newly diagnosed multiple myeloma.
Genomic Features May Define Patient Selection in KRAS-mutated NSCLC
Adagrasib elicited higher efficacy in combination with mTOR inhibitors vs alone when treating patients with KRASG12C-mutant non–small cell lung cancer.
Blood-Based Test May Help Increase Colorectal Cancer Screening Rates
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
CHMP Recommends EU Approval for Durvalumab in Limited-Stage SCLC
Support for the recommendation is based on phase 3 ADRIATIC trial results showing a 27% reduction in the risk of death with durvalumab vs placebo.
FDA Accepts BLA for Pertuzumab Biosimilar in HER2+ Breast Cancer
Data from analytical similarity studies and comparative clinical trials support the application of HLX11 in HER2-positive breast cancer.
Integrative Oncology Approaches to Managing Gastrointestinal Cancer
Options like acupuncture or cannabis use may be viable to help manage symptoms related to gastrointestinal cancer treatment.
